

Table 13 (Continued)

Summary of average body weight (g) and number of surviving rats (2-year carcinogenicity study)

	WEEK 81	WEEK 85	WEEK 89	WEEK 93	WEEK 97
<b>Male</b>					
Control	(48) 476 ± 28	(47) 476 ± 28	(45) 486 ± 33	(44) 479 ± 28	(43) 478 ± 27
0.03%	(47) 507 ± 32 *	(46) 504 ± 32 *	(45) 508 ± 33 *	(45) 501 ± 34 *	(44) 493 ± 37
0.5%	(48) 485 ± 28	(47) 483 ± 27	(45) 486 ± 24	(43) 478 ± 25	(42) 475 ± 27
2%	(44) 436 ± 24 *	(44) 433 ± 24 *	(42) 440 ± 25 *	(41) 438 ± 26 *	(37) 431 ± 22 *
<b>Female</b>					
Control	(45) 264 ± 24	(44) 270 ± 25	(44) 275 ± 26	(42) 282 ± 28	(40) 286 ± 25
0.03%	(46) 290 ± 25 *	(46) 297 ± 26 *	(46) 306 ± 27 *	(45) 311 ± 28 *	(45) 315 ± 28 *
0.5%	(50) 277 ± 22 *	(50) 283 ± 24 *	(50) 291 ± 26 *	(50) 292 ± 26	(48) 294 ± 27
2%	(48) 243 ± 14 *	(48) 247 ± 16 *	(48) 255 ± 17 *	(47) 257 ± 17 *	(47) 260 ± 18 *

\* Significantly different from corresponding control group.

Table 13 (Continued)

Summary of average body weight (g) and number of surviving rats (2-year carcinogenicity study)

	WEEK 101	WEEK 103	WEEK 104
Male			
Control	(43) 480 ± 30	(43) 471 ± 32	(43) 471 ± 34
0.03%	(41) 493 ± 37	(41) 482 ± 43	(41) 481 ± 44
0.5%	(40) 470 ± 25	(40) 458 ± 27	(40) 456 ± 27
2%	(29) 431 ± 25 *	(27) 421 ± 26 *	(22) 417 ± 29 *
Female			
Control	(40) 288 ± 25	(37) 283 ± 26	(37) 283 ± 26
0.03%	(44) 319 ± 30 *	(43) 317 ± 31 *	(43) 316 ± 31 *
0.5%	(47) 298 ± 28	(47) 292 ± 28	(46) 292 ± 29
2%	(43) 265 ± 19 *	(42) 262 ± 22 *	(42) 261 ± 22 *

\* Significantly different from corresponding control group.

Table 14

Food intake (g/day/rat) in 2-year carcinogenicity study

Sex	Treatment	Week											
		1	2	3	4	5	6	7	8	9	10	11	12
Male	Control	12.6	14.0	15.0	14.9	15.3	14.5	14.3	14.2	13.9	13.2	13.7	13.1
	0.03%	13.2 *	14.6 *	15.5 *	15.7 *	16.3 *	15.4 *	15.3 *	15.1 *	14.8 *	14.2 *	14.5 *	13.8 *
	0.5%	13.6 *	15.1 *	16.1 *	16.1 *	16.6 *	15.6 *	15.7 *	15.5 *	15.0 *	14.4 *	14.6 *	14.0 *
	2%	12.9	14.6 *	15.5	15.4	15.9 *	15.2 *	14.7	14.9 *	14.3 *	13.7 *	14.0	13.2
Female	Control	9.7	7.1	10.1	9.3	10.1	9.8	9.3	9.1	10.2	8.7	9.0	8.6
	0.03%	10.2 *	9.4 *	10.5	10.2 *	10.5	10.0	9.7 *	9.7 *	9.5	9.1 *	9.3 *	8.9
	0.5%	10.5 *	10.2 *	10.3	10.3 *	10.5 *	9.9	9.7 *	9.6 *	9.2	8.9	9.0	8.8
	2%	10.2 *	9.9 *	10.2	9.7	9.9	9.9	9.2	9.2	9.0	8.4	9.1	8.6

\* Significantly different from corresponding control group.

Table 14 (Continued)

Food intake (g/day/rat) in 2-year carcinogenicity study

Sex	Treatment	Week												
		13	14	18	22	26	30	34	38	42	46	50	54	
Male	Control	13.0	12.9	13.7	13.6	13.9	13.5	13.3	13.3	13.3	13.7	13.7	13.5	
	0.03%	14.0 *	13.7 *	15.0 *	14.8 *	15.0 *	14.5 *	14.5 *	14.3 *	14.5 *	14.6 *	14.7 *	14.4 *	
	0.5%	14.0 *	13.6 *	15.2 *	14.4 *	14.8 *	15.2 *	14.2 *	14.3 *	14.4 *	14.2 *	14.6 *	14.1 *	
	2%	13.7	13.0	14.8 *	13.4	14.9 *	14.3 *	13.7	14.3 *	14.2 *	14.5 *	14.4 *	14.0	
Female	Control	8.5	8.0	8.4	8.2	8.2	8.3	7.8	8.2	8.2	8.4	8.8	8.8	
	0.03%	9.1 *	8.4 *	9.0 *	8.7 *	9.1 *	8.5 *	8.5 *	8.8 *	8.9 *	8.7	9.2 *	9.1	
	0.5%	9.1 *	7.9	8.8 *	8.2	8.7 *	8.6 *	8.2 *	8.4	8.8	8.6	9.4 *	9.2 *	
	2%	8.7	7.8	8.5	8.2	8.5	8.4	8.2	8.5	8.5	8.4	8.7	9.0	

\* Significantly different from corresponding control group.

Table 14 (Continued)  
Food intake (g/day/rat) in 2-year carcinogenicity study

Sex	Treatment	Week												
		59	62	66	70	74	78	82	86	90	94	98	102	104
Male	Control	13.3	13.2	13.3	14.2	14.0	13.4	14.0	14.1	13.7	13.6	13.8	13.4	12.5
	0.03%	14.4 *	14.2 *	13.8 *	15.1 *	15.3 *	14.9 *	14.9 *	14.9	14.4 *	14.1	13.5	13.8	12.7
	0.5%	14.3 *	13.9 *	13.8 *	15.0 *	14.6 *	14.5 *	14.6	14.3	13.6	13.9	14.0	13.8	12.6
	2%	14.1 *	13.6 *	13.5	14.6	14.7 *	14.0 *	14.5	14.4	14.4 *	14.3	14.3	14.0	11.4
Female	Control	9.2	8.5	8.8	9.1	9.6	9.4	9.4	9.5	9.7	9.5	9.9	9.6	8.8
	0.03%	9.8	8.6	8.9	9.8 *	10.3 *	10.1 *	10.1	10.0	10.3	10.0	10.2	9.8	9.1
	0.5%	9.4	8.7	8.9	9.4 *	10.1	10.0 *	9.7	9.9	9.7	9.9	9.8	9.8	8.8
	2%	9.4	8.5	8.7	9.1	9.5	9.5	9.5	9.7	9.7	9.8	9.6	9.8	9.3

\* Significantly different from corresponding control group.

Table 15

## Intake of dammar resin of F344 rats in 2-year toxicity study

Sex	Treatment	Total intake of dammar resin (mg/kg b.w.)	Average intake of dammar resin (mg/kg b.w./day)
Male	Control	0	0
	0.03%	7639.80	10.49
	0.5%	129786.93	178.28
	2%	558269.67	766.85
Female	Control	0	0
	0.03%	8874.67	12.19
	0.5%	149549.75	205.43
	2%	631947.19	868.06

Table 16

Water intake (g/day/rat) in 2-year carcinogenicity study

Sex	Treatment	Week											
		1	2	3	4	5	6	7	8	9	10	11	12
Male	Control	19.3	20.4	21.4	21.5	20.9	21.4	20.1	20.3	20.4	19.8	19.7	18.9
	0.03%	20.2	21.3	22.6	22.8 *	21.9	22.2	21.1 *	21.0	21.1	21.0 *	20.2	19.6
	0.5%	20.8 *	22.9 *	24.2 *	23.7 *	22.7 *	23.2 *	21.6 *	21.8 *	21.9 *	21.6 *	21.2 *	20.2 *
	2%	20.1	21.7	23.2 *	23.7 *	22.9 *	24.4 *	22.3 *	23.1 *	23.3 *	22.7 *	22.1 *	21.0 *
Female	Control	17.4	17.6	17.0	17.5	17.9	17.4	16.4	16.4	17.2	16.2	16.7	15.2
	0.03%	17.0	17.3	17.0	17.4	17.4	16.6	15.8	16.1	16.7	16.4	16.2	14.8
	0.5%	16.8	17.1	16.8	16.7	16.9	16.3	15.4	15.7	16.4	15.9	16.4	15.1
	2%	15.3 *	16.1 *	17.4	17.7	18.6	17.5	16.1	17.0	17.7	17.0	18.1 *	15.5

\* Significantly different from corresponding control group.

Table 16 (Continued)  
Water intake (g/day/rat) in 2-year carcinogenicity study

Sex	Treatment	Week												
		13	14	18	22	26	30	34	38	42	46	50	54	
Male	Control	19.4	18.2	18.0	17.4	16.0	15.4	15.1	15.6	15.4	15.7	16.0	16.4	
	0.03%	20.5	18.8	18.4	17.8	16.7	16.0	15.9	16.1	15.9	16.1	16.8 *	17.4 *	
	0.5%	20.9 *	19.2	18.8	18.3	16.9 *	16.3 *	16.2 *	16.2	16.2 *	15.9	16.6	17.2 *	
	2%	22.6 *	21.2 *	21.0 *	20.9 *	19.0 *	18.2 *	17.6 *	17.6 *	17.7 *	17.5 *	17.8 *	18.5 *	
Female	Control	15.7	15.0	14.4	15.3	13.3	13.1	13.1	13.2	11.8	12.9	12.9	13.6	
	0.03%	15.4	14.4	14.1	14.7	12.8	12.6	12.8	13.1	11.7	12.5	12.7	13.7	
	0.5%	15.3 *	14.5	13.6	14.4	12.8	12.6	12.3 *	12.6	11.4	12.6	12.8	13.3	
	2%	16.3	15.2	14.4	16.2	13.4	12.9	13.2	13.6	11.4	13.1	12.7	13.8	

\* Significantly different from corresponding control group.



Table 16 (Continued)  
Water intake (g/day/rat) in 2-year carcinogenicity study

Sex	Treatment	Week												
		59	62	66	70	74	78	82	86	90	94	98	102	104
Male	Control	17.1	17.3	17.3	17.4	16.6	15.7	16.5	17.0	17.0	17.8	18.2	19.4	21.2
	0.03%	18.3 *	18.7 *	18.6 *	18.7 *	17.9 *	16.9 *	17.3 *	18.3 *	18.6 *	19.2 *	19.5 *	21.1 *	22.4 *
	0.5%	18.0 *	18.4 *	19.1 *	18.8 *	17.5 *	17.3 *	17.5 *	17.8 *	18.4 *	19.2 *	20.1 *	22.5 *	24.8 *
	2%	20.0 *	19.8 *	19.9 *	19.7 *	18.2 *	17.0 *	17.0 *	18.2 *	18.9 *	19.5 *	18.7 *	20.3 *	21.2 *
Female	Control	13.5	14.2	14.5	13.9	14.6	13.2	13.1	13.6	14.1	13.9	14.4	14.7	15.7
	0.03%	12.8 *	13.8 *	14.3 *	13.9 *	14.5 *	13.2 *	13.6 *	14.3 *	16.6 *	13.8 *	14.0 *	14.9 *	16.0 *
	0.5%	12.8 *	14.0 *	14.2 *	13.9 *	15.0 *	13.3 *	13.0 *	13.4 *	14.0 *	14.5 *	14.5 *	15.1 *	16.0 *
	2%	13.1 *	14.6 *	14.8 *	14.3 *	15.1 *	13.5 *	13.0 *	13.6 *	14.7 *	15.0 *	14.9 *	15.8 *	17.1 *

\* Significantly different from corresponding control group.

Table 17A

Hematology data (2-year carcinogenicity study)

Treatment	No. of rats rat examined	RBC $\times 10^4/\mu\text{l}$	Hb g/dl	Ht %	PLT $\times 10^4/\mu\text{l}$
<b>Male</b>					
Control	17	873 $\pm$ 135	14.6 $\pm$ 2.4	48.5 $\pm$ 7.3	65.8 $\pm$ 8.1
0.03%	10	851 $\pm$ 40	14.3 $\pm$ 0.5	48.1 $\pm$ 1.1	61.5 $\pm$ 4.0
0.5%	9	867 $\pm$ 41	14.4 $\pm$ 0.7	49.1 $\pm$ 2.7	70.7 $\pm$ 4.9
2%	17	747 $\pm$ 107 *	11.9 $\pm$ 1.9 *	42.2 $\pm$ 5.8 *	76.2 $\pm$ 11.4 *
<b>Female</b>					
Control	10	794 $\pm$ 54	14.4 $\pm$ 1.3	44.9 $\pm$ 3.2	52.2 $\pm$ 9.0
0.03%	10	790 $\pm$ 32	14.2 $\pm$ 0.5	44.9 $\pm$ 1.8	50.6 $\pm$ 8.0
0.5%	10	784 $\pm$ 33	14.0 $\pm$ 1.5	45.1 $\pm$ 4.1	58.3 $\pm$ 12.5
2%	10	785 $\pm$ 44	13.6 $\pm$ 1.0	45.4 $\pm$ 3.2	69.4 $\pm$ 5.4 *

\* Significantly different from control group.

Table 17 A (Continued)  
Hematology data (2-year carcinogenicity study)

Treatment	No. of rats rat examined	MCV fl	MCH pg	MCHC %	WBC / $\mu$ l
Male					
Control	17	56 $\pm$ 3	16.8 $\pm$ 0.7	30.1 $\pm$ 1.5	3400 $\pm$ 1320
0.03%	10	57 $\pm$ 2	16.8 $\pm$ 0.5	29.6 $\pm$ 1.0	3580 $\pm$ 605
0.5%	9	57 $\pm$ 3	16.6 $\pm$ 0.6	29.3 $\pm$ 0.7	2744 $\pm$ 600
2%	17	57 $\pm$ 2	15.9 $\pm$ 0.5 *	28.2 $\pm$ 1.0 *	2956 $\pm$ 715
Female					
Control	10	56 $\pm$ 3	18.1 $\pm$ 1.0	32.0 $\pm$ 1.1	2790 $\pm$ 1343
0.03%	10	57 $\pm$ 2	18.0 $\pm$ 0.5	31.6 $\pm$ 0.7	2150 $\pm$ 725
0.5%	10	57 $\pm$ 4	17.8 $\pm$ 1.4	31.0 $\pm$ 0.8	2600 $\pm$ 1265
2%	10	58 $\pm$ 2	17.3 $\pm$ 0.4 *	29.9 $\pm$ 0.7 *	2240 $\pm$ 458

\* Significantly different from control group.

Table 17 B  
Hematology data (2-year carcinogenicity study)

Treatment	No. of rats rat examined	PT(s) sec.	Fibrinogen mg/dl	APTT (sec.)	
				<20	□20, <25 □25
<b>Male</b>					
Control	8	8.3 ± 0.1	259 ± 22	8	0
0.03%	8	8.3 ± 0.2	273 ± 40	8	0
0.5%	7	11.2 ± 2.4 *	313 ± 48 *	3	4*
2%	-				
<b>Female</b>					
Control	8	9.1 ± 0.5	204 ± 46	0	4
0.03%	8	8.4 ± 0.5	211 ± 14	3	3
0.5%	8	8.2 ± 0.2 *	220 ± 18	2	4
2%	8	16.0 ± 9.6	256 ± 18 *	0	3

\* Significantly different from control group.

□, no examined.

Table 18  
Serum chemistry data (2-year carcinogenicity study)

Treatment	No. of rats	T-BIL mg/dl	AST IU/l	ALT IU/l	r-GTP IU/l	ALP IU/l	TP g/dl
<b>Male</b>							
Control	17	0.11 ± 0.03	140 ± 35	48 ± 19	3.2 ± 2.2	282 ± 58	6.7 ± 0.5
0.03%	10	0.11 ± 0.03	118 ± 19	47 ± 12	3.8 ± 2.0	291 ± 76	6.9 ± 0.2
0.5%	9	0.10 ± 0.00	101 ± 12*	36 ± 5	5.3 ± 2.1	255 ± 31	6.9 ± 0.2
2%	17	0.10 ± 0.00	58 ± 8*	33 ± 7	5.2 ± 2.4*	229 ± 38*	6.3 ± 0.5*
<b>Female</b>							
Control	10	0.10 ± 0.00	186 ± 57	65 ± 19	1.2 ± 0.6	224 ± 98	7.4 ± 0.5
0.03%	10	0.10 ± 0.00	167 ± 90	51 ± 24	1.2 ± 0.4	167 ± 55	7.3 ± 0.6
0.5%	10	0.10 ± 0.00	103 ± 36*	38 ± 11*	3.5 ± 1.1*	158 ± 34	7.7 ± 0.5
2%	10	0.10 ± 0.00	71 ± 9*	37 ± 3*	10.5 ± 2.6*	142 ± 37	7.7 ± 0.4

\* Significantly different from control group.

Table 18 (Continued)  
Serum chemistry data (2-year carcinogenicity study)

Treatment	No. of rats	ALB g/dl	A/G	Cre mg/dl	BUN mg/dl	T-Cho mg/dl	TG mg/dl
Male							
Control	17	4.0 ± 0.4	1.5 ± 0.3	0.31 ± 0.04	19.3 ± 4.4	159 ± 44	104 ± 45
0.03%	10	4.2 ± 0.3	1.6 ± 0.2	0.33 ± 0.05	17.9 ± 2.3	174 ± 30	157 ± 66*
0.5%	9	4.0 ± 0.3	1.4 ± 0.2	0.34 ± 0.06	20.4 ± 1.9	196 ± 45	153 ± 69
2%	17	3.7 ± 0.3	1.5 ± 0.2	0.29 ± 0.04	23.0 ± 5.3	171 ± 41	107 ± 46
Female							
Control	10	4.9 ± 0.4	2.1 ± 0.3	0.27 ± 0.05	21.0 ± 3.4	121 ± 14	88 ± 23
0.03%	10	4.9 ± 0.3	2.1 ± 0.3	0.27 ± 0.05	18.3 ± 3.6	124 ± 19	122 ± 54
0.5%	10	5.0 ± 0.3	2.0 ± 0.3	0.26 ± 0.05	18.4 ± 3.5	142 ± 19	127 ± 42
2%	10	5.2 ± 0.3	2.0 ± 0.0	0.26 ± 0.02	21.8 ± 4.1	191 ± 34*	114 ± 40

\* Significantly different from control group.

Table 18 (Continued)  
Serum chemistry data (2-year carcinogenicity study)

Treatment	No. of rats	Na mEq/l	K mEq/l	Cl mEq/l	Ca mg/dl	IP mg/dl
<b>Male</b>						
Control	17	144 ± 1	4.8 ± 0.4	101 ± 2	10.49 ± 0.29	5.8 ± 1.1
0.03%	10	143 ± 1	4.6 ± 0.2	101 ± 1	10.69 ± 0.20	5.6 ± 0.6
0.5%	9	143 ± 1	4.7 ± 0.1	100 ± 1	10.76 ± 0.13*	5.8 ± 0.6
2%	17	143 ± 1	4.1 ± 0.4	102 ± 1	10.71 ± 0.27*	5.1 ± 0.4
<b>Female</b>						
Control	10	144 ± 1	4.3 ± 0.3	103 ± 2	10.33 ± 0.23	4.1 ± 0.7
0.03%	10	144 ± 2	4.3 ± 0.3	102 ± 1	10.46 ± 0.20	4.2 ± 0.7
0.5%	10	144 ± 1	4.5 ± 0.3	102 ± 1	10.60 ± 0.24*	4.2 ± 0.6
2%	10	142 ± 1	4.4 ± 0.5	102 ± 1	10.77 ± 0.29*	4.4 ± 0.3

\* Significantly different from control group.

Table 19  
Urinalysis data (2-year carcinogenicity study)

Treatment	No. of animal	Protein			Glucose			Ketone		
		-	+/-	≥300mg/dl	-	100mg/dl	-	+/-	1+	2+
<b>Male</b>										
Control	11	0	0	0	11	11	0	3	8	0
0.03%	11	0	0	0	11	11	0	1	5	0
0.5%	12	0	0	0	12	12	0	1	5	0
2%	11	0	0	0	11	11	0	0	11	0
<b>Female</b>										
Control	14	0	1	4	3	6	14	0	5	2
0.03%	10	0	0	3	4	3	9	1	4	6
0.5%	12	0	0	0	5	7	12	0	3	4
2%	11	0	0	0	2	9	11	0	3	8



Table 19 (Continued)  
Urinalysis data (2-year carcinogenicity study)

Treatment	No. of animal	Specific gravity				Occult blood				Bilirubin			
		1.015	1.020	1.025	$\geq 1.030$	-	+/-	1+	2+	3+	-	1+	2+
<b>Male</b>													
Control	11	0	3	7	1	10	0	0	0	1	1	10	0
0.03%	11	0	1	9	1	10	0	0	0	1	4	7	0
0.5%	12	0	0	10	2	12	0	0	0	0	5	7	0
2%	11	0	6	5	0	10	1	0	0	0	8	3	0
<b>Female</b>													
Control	14	0	2	6	6	12	1	0	0	1	6	8	0
0.03%	10	0	3	4	3	9	0	0	0	1	1	8	1
0.5%	12	0	3	5	4	12	0	0	0	0	4	8	0
2%	11	0	4	7	0	11	0	0	0	0	1	10	0

Table 19 (Continued)

Urinalysis data (2-year carcinogenicity study)

Treatment	No. of animal	pH			Urobilinogen		Nitrite		
		7.0	7.5	8.0	8.5	0.1 E.U./dl		1.0 E.U./dl	
<b>Male</b>									
Control	11	1	8	1	1	3	8	11	0
0.03%	11	4	5	1	1	4	7	11	0
0.5%	12	5	6	0	0	4	8	12	0
2%	11	1	2	4	4	8	3	11	0
<b>Female</b>									
Control	14	3	9	2	0	8	6	14	0
0.03%	10	3	4	2	1	1	9	10	0
0.5%	12	3	6	3	0	4	8	12	0
2%	11	0	8	3	0	4	7	11	0

Table 20

## Organ weights (2-year carcinogenicity study)

Treatment	No. of animal	Liver		Kidney		Spleen	
		Absolute (g)	Relative (%)	Absolute (g)	Relative (g)	Absolute (g)	Relative (%)
<b>Male</b>							
Control	43	11.0 ± 1.1	2.3 ± 0.2	2.75 ± 0.29	0.59 ± 0.08	1.07 ± 0.18	0.2 ± 0.0
0.03%	41	12.1 ± 1.0 *	2.5 ± 0.3 *	2.87 ± 0.19 *	0.60 ± 0.07	1.36 ± 0.97	0.3 ± 0.3
0.5%	40	13.4 ± 1.6 *	2.9 ± 0.3 *	2.90 ± 0.28 *	0.64 ± 0.07 *	1.38 ± 1.77	0.3 ± 0.4
2%	22	14.7 ± 3.1 *	3.6 ± 1.0 *	2.78 ± 0.11	0.67 ± 0.04 *	1.44 ± 1.48 *	0.3 ± 0.3
<b>Female</b>							
Control	37	6.2 ± 1.0	2.2 ± 0.3	1.76 ± 0.17	0.63 ± 0.09	0.72 ± 0.53	0.3 ± 0.2
0.03%	43	6.7 ± 1.0 *	2.1 ± 0.2	1.81 ± 0.11	0.58 ± 0.05 *	0.59 ± 0.18	0.2 ± 0.1
0.5%	46	7.8 ± 1.5 *	2.7 ± 0.4 *	1.85 ± 0.21 *	0.64 ± 0.11	0.76 ± 0.96	0.3 ± 0.3
2%	42	8.8 ± 1.4 *	3.4 ± 0.4 *	1.78 ± 0.12	0.68 ± 0.06 *	0.73 ± 0.93 *	0.3 ± 0.4

\* Significantly different from control group.

Table 20 (Continued)

Organ weights (2-year carcinogenicity study)

Treatment	No. of animal	Heart		Brain		Adrenal	
		Absolute (g)	Relative (%)	Absolute (g)	Relative (%)	Absolute (g)	Relative (%)
<b>Male</b>							
Control	10	1.23 ± 0.15	0.26 ± 0.03	2.12 ± 0.06	0.45 ± 0.03	0.12 ± 0.33	0.027 ± 0.081
0.03%	10	1.26 ± 0.13	0.26 ± 0.03	2.13 ± 0.06	0.45 ± 0.04	0.07 ± 0.02	0.014 ± 0.003
0.5%	10	1.25 ± 0.09	0.27 ± 0.03	2.10 ± 0.06	0.46 ± 0.03	0.07 ± 0.02	0.014 ± 0.005
2%	10	1.19 ± 0.06	0.29 ± 0.03 *	2.09 ± 0.05	0.50 ± 0.03 *	0.07 ± 0.03	0.014 ± 0.003
<b>Female</b>							
Control	10	0.80 ± 0.06	0.29 ± 0.03	1.90 ± 0.06	0.68 ± 0.07	0.07 ± 0.01	0.024 ± 0.005
0.03%	10	0.84 ± 0.06 *	0.27 ± 0.03 *	1.92 ± 0.05	0.62 ± 0.06 *	0.08 ± 0.12	0.027 ± 0.042
0.5%	10	0.84 ± 0.06 *	0.29 ± 0.03	1.91 ± 0.06	0.66 ± 0.08	0.06 ± 0.01	0.020 ± 0.004
2%	10	0.81 ± 0.05	0.31 ± 0.02 *	1.90 ± 0.06	0.73 ± 0.06 *	0.05 ± 0.01 *	0.019 ± 0.003

\* Significantly different from control group.